TrialBMC cancer2018

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.

Loïc Lebellec et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.